Nivolumab Improves Survival for Patients with Recurrent Head and Neck Cancer
A summary of clinical trial results showing that nivolumab (Opdivo®) improved overall survival compared with standard chemotherapy in patients with head and neck squamous cell carcinoma.
Media Type: Html
- SourceUrl: https://www.cancer.gov/node/1070677/syndication
- Syndication ID: 16473
- Language: English
- Source: National Cancer Institute (NCI)
- Date Syndication Captured: Wednesday, January 04, 2017 at 10:10 PM
- Date Syndication Updated: Monday, August 05, 2019 at 07:40 PM
Embed Code Snippet
To get the embed code snippet please Login.
